AFT Pharmaceuticals Limited — Investor Relations & Filings

AFT Pharmaceuticals Limited focuses on the development, licensing, and distribution of pharmaceutical products across a broad range of therapeutic categories. The company’s core portfolio includes pain management, dermatology, eye care, and hospital-based medicines. Its flagship product, Maxigesic, is a patented combination of paracetamol and ibuprofen available in multiple dosage forms and marketed globally. AFT Pharmaceuticals emphasizes research and development to create innovative delivery systems and therapeutic solutions. The company operates through a combination of direct sales in specific regions and international licensing agreements, reaching markets in over 100 countries. Its product range spans over-the-counter (OTC) and prescription medications, targeting both retail pharmacy and clinical environments.